Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: AI Image
Lead poisoning is a widespread but preventable health threat that contributes to more than 3.5 million deaths globally each year and puts hundreds of millions of children at risk, the World Health Organization (WHO) said.
Marking International Lead Poisoning Prevention Week 2026, WHO urged countries to accelerate prevention efforts amid growing global momentum to tackle lead exposure.
Also read: Lead Found In Everyday Vegetables - Reveals A Bengaluru Study
Children are particularly vulnerable to lead because their developing brains and nervous systems are highly susceptible to its toxic effects. Even low levels of exposure can cause irreversible harm, affecting learning, behavior and development.
“Lead poisoning should not be stealing children's potential in 2026,” said Bruce Gordon, Director a.i. of WHO’s Department of Environment, Climate Change, One Health and Migration.
“We know where many exposures come from and we know how to prevent them. Countries now need to move upstream, removing lead from products and environments before it reaches a child's bloodstream. WHO is working with governments and partners to help turn that evidence into action,” Gordon added.
There is no known safe level of lead exposure, WHO warned. Exposure can occur through paint, cookware, cosmetics, spices, informal recycling and industrial contamination, among other sources.
Lead affects multiple organs and can contribute to cardiovascular and kidney disease in adults. In children, exposure can cause lasting damage to brain function and development. Its effects may go undetected until significant harm has occurred.
Lead is distributed to the brain, liver, kidney and bones. It is stored in the teeth and bones, where it can accumulate over time. Human exposure is assessed through the measurement of lead in blood.
Fewer than half of countries had confirmed legally binding controls on lead paint, according to WHO's latest published global assessment.
This year's International Lead Poisoning Prevention Week theme, “From Detection to Prevention,” highlights the need for stronger policies, better enforcement of safety standards and greater public awareness to eliminate lead hazards at their source.
WHO Member States have recognized lead exposure as a pressing public health concern and mandated the development of a Global Action Plan on Lead Mitigation, which will be presented to the World Health Assembly in 2027.
The WHO will also launch the PREVENT Technical Package on Lead Poisoning Prevention in 2027. It will provide practical guidance to help countries identify major exposure sources, prioritize interventions, strengthen regulations and track progress.
Last year, WHO joined partners in the Lead Poisoning Prevention Initiative to strengthen laboratory capacity for blood lead testing, supporting the monitoring and early detection of exposure.
The initiative will provide technical support and build laboratory capacity in Brazil, five states in India, Nepal and six sub-Saharan African countries: Ethiopia, Ghana, Malawi, Rwanda, South Africa and the United Republic of Tanzania.
Preventing lead exposure can also reduce health care costs, improve educational outcomes and support healthier, more productive societies.
The WHO urged countries to move beyond detecting lead exposure and adopt comprehensive prevention strategies such as:
Credit: BBC/PA News Agency
Scottish swimmer Archie Goodburn has welcomed the UK government’s plans to review progress in brain cancer research after years of campaigning for better treatment and greater investment in research.
Goodburn, 25, revealed in 2024 that he had been diagnosed with three inoperable brain tumors. In August, he broke down during an interview on BBC Breakfast as he spoke about the challenges faced by patients with brain cancer and their families.
He appealed to the government to invest more in research, urging it to “give us a chance to fight for our lives.” His plea led to a meeting with Prime Minister Andy Burnham.
The government has now announced a new national brain cancer clinical lead and a review of progress in brain cancer research, with the aim of helping patients access treatments sooner, the BBC reported.
Goodburn thanked the prime minister, saying all three of his requests had been “promised to some extent,” although the details still needed to be worked out.
Burnham described Goodburn as an “inspiration to us all” and said he was “delighted” to welcome him to Downing Street.
“He has spoken passionately about the need for change on brain cancer, and he's right: progress hasn't been good enough, here or anywhere else. Families facing this disease can't afford to wait,” Burnham said.
According to the BBC, the review will be led by Professor Anthony Chalmers, chair of clinical oncology at the University of Glasgow. It will assess progress in brain cancer research since 2018 and identify “what is still holding progress back.”
The review will be followed by a national cancer plan aimed at getting new treatments “out of the lab and to patients faster,” Downing Street said.
The prime minister has also asked the Medicines and Healthcare products Regulatory Agency (MHRA) to complete its review of regulations for medicines used to treat rare conditions sooner.
Goodburn has urged the regulator to finish the review within two years rather than three, bringing forward potential changes that could help patients access new treatments sooner.
Read More: Saba Ali Khan Opens Up About Brain Tumour: Can It Go Unnoticed If You Walk, Talk And Work Normally?
Scottish First Minister John Swinney, who also recently met Goodburn, highlighted the Scottish government's commitment to supporting more clinical trials.
“We are proud to support national leadership for brain cancer through the Scottish Adult Neuro-Oncology Network,” Swinney said.
The network brings together clinicians, patients and voluntary sector representatives to improve care for people with brain cancer across Scotland.
“We will give careful consideration to any further role which Scotland could play to give people living with brain cancer a faster route from research to treatment,” he added.
READ: Survival In Aggressive Brain Tumors Improves By Up To 50% in India, Say Doctors
The Edinburgh-born swimmer sought medical tests after experiencing numbness and seizures while training for the 2024 Olympic trials. He was diagnosed with three large oligodendrogliomas, a rare type of tumor that can affect the brain and spinal cord.
He underwent chemotherapy and radiotherapy, but surgery to remove the tumors was not possible.
Despite his diagnosis, Goodburn competed at the 2026 Commonwealth Games in Glasgow, reaching the final of the 50-meter breaststroke but narrowly missing out on a medal.
Charity Brain Tumour Research has described brain tumors as the cancer most likely to kill people under 40 in the UK.
“One of my dreams is that we see a future where brain cancer isn't the biggest killer of patients under 40,” Goodburn said during the Commonwealth Games.
Credit: AI
Retatrutide, an experimental loss drug being called the 'Godzilla' of weight loss jabs, has been reported to cause 129 symptoms, including burning sensation on skin, panic attack, a racing heartbeat and depression. It earned the nickname after clinical trials indicated that it could be more powerful than Ozempic and Mounjaro.
The discovery has raised concerns, especially amid the growing use of the drug outside clinical trials. Retatrutide is still being studied and has not yet been approved for general use but it is being bought illegally in the UK as well as across the world.
According to Daily Mail, researchers from the University of Pennsylvania, analysed 148,640 Reddit posts related to retatrutide and identified 13,589 users who claimed to be taking retatrutide and analysed the side effects they reported. Of these, 7,823 reported at least one side effect, researchers identified 129 different symptoms.
The reports included physical symptoms as well as psychological complaints. But it does not prove that this weight loss drug is directly responsible for these side effects. The study was published in JAMA Network Open.
Social media reports can help identify safety concerns, but they have limitations. Researchers cannot independently verify every user’s medical history, the product they took, its ingredients or whether another condition could explain their symptoms.
The side effects were split into 14 different categories, including gastrointestinal problems, mental disorders, heart problems and skin changes. The most common side effect was increased appetite surprisingly which was seen in almost one in five users, affecting 1,336 people.
Fatigue was the second most reported symptom, which was flagged by around 15% of the users, which means almost 1, 188 patients. Nausea, on the other hand, was on top of the list of gastrointestinal issues, affecting fewer than one in 10.
Retatrutide is being developed by pharmaceutical company Eli Lilly as a treatment for obesity. It works on three hormone receptors involved in regulating appetite, blood sugar and energy balance: GIP, GLP-1 and glucagon.
The drug has attracted attention because clinical trials have shown substantial weight loss. In a Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose lost an average of 24.2% of their body weight over 48 weeks.
It also delivered nearly 21% average weight loss in people with type 2 diabetes and obesity, according to results from a large Phase 3 trial published in The Lancet.
In the TRIUMPH-2 trial, people who received the highest 12 mg dose lost an average of 20.8% of their body weight over 80 weeks, equivalent to about 49.6 pounds or 22.5 kg.
However, promising results do not mean the drug is suitable for unsupervised use, especially since it is unapproved.
Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs
In controlled clinical trials, the most frequently reported side effects have included nausea, diarrhoea, vomiting and constipation. These gastrointestinal problems were generally more common at higher doses and during dose increases.
Researchers have also reported increased heart rate and skin sensitivity in some participants. In the Phase 2 trial, adverse events related to skin sensitivity were reported in 7% of participants receiving retatrutide, compared with 1% in the placebo group.
The symptoms reported in online discussions, including panic attacks and depression, require careful interpretation. Their appearance in user posts does not, by itself, prove that the drug caused them or establish how frequently they occur among people taking retatrutide under medical supervision.
Retatrutide remains under study, which means its safety profile is still being assessed by researchers. Products sold online or through unlawful ways may not contain the right advertised drug.
Professor Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, warned against purchasing unlicensed weight-loss products online. “I would urge people to avoid buying unlicensed weight-loss products online,” he said, according to Daily Mail. “There is no certainty about what these products contain, and without proper regulatory oversight there is a risk of adverse effects.”
© $2026 Times Horizon Private Limited